164 related articles for article (PubMed ID: 12605565)
1. Recent advances in the pharmacological treatment of colorectal cancer.
Messersmith W; Laheru D; Hidalgo M
Expert Opin Investig Drugs; 2003 Mar; 12(3):423-34. PubMed ID: 12605565
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of colorectal cancer.
Tebbutt NC; Cattell E; Midgley R; Cunningham D; Kerr D
Eur J Cancer; 2002 May; 38(7):1000-15. PubMed ID: 11978525
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
O'Neil BH
Semin Radiat Oncol; 2003 Oct; 13(4):441-53. PubMed ID: 14586833
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic agents.
Stani SC; Capaccetti B; Bonginelli P; Sarmiento R; De Sio L; Fanelli M; Gasparini G
Suppl Tumori; 2002; 1(4):S39-43. PubMed ID: 12415816
[No Abstract] [Full Text] [Related]
6. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
7. [[Last news from ASCO 2000 in the topic of colorectal cancer] ].
Sobrero A
Tumori; 2000; 86(3):A1-2. PubMed ID: 10939611
[No Abstract] [Full Text] [Related]
8. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
Hecht JR
Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
[TBL] [Abstract][Full Text] [Related]
9. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
10. [Management of metastatic colorectal cancer].
Tournigand C; Bengrine-Lefevre L; Chibaudel B; de Gramont A
Rev Prat; 2010 Oct; 60(8):1103-7. PubMed ID: 21197743
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted agents in the treatment of lung cancer.
Saba N; Khuri F
Expert Opin Investig Drugs; 2004 Jun; 13(6):609-29. PubMed ID: 15174948
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
13. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Becerra CR; Frenkel EP; Ashfaq R; Gaynor RB
Int J Cancer; 2003 Jul; 105(6):868-72. PubMed ID: 12767075
[TBL] [Abstract][Full Text] [Related]
14. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Damjanovic D; Thompson P; Findlay MP
ANZ J Surg; 2004 Sep; 74(9):781-7. PubMed ID: 15379811
[TBL] [Abstract][Full Text] [Related]
16. Developments in combination chemotherapy for colorectal cancer.
Goetz MP; Grothey A
Expert Rev Anticancer Ther; 2004 Aug; 4(4):627-37. PubMed ID: 15270666
[TBL] [Abstract][Full Text] [Related]
17. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Schmoll HJ
Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
[TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of colorectal cancer: present advances].
Goldwasser F
Presse Med; 2012 Jan; 41(1):44-5. PubMed ID: 22138291
[No Abstract] [Full Text] [Related]
20. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Sanborn R; Blanke CD
Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
